Abstract
Cholecystokinin (CCK) is a peptide widely distributed in the central nervous system. Since its characterization in the porcine intestine, evidence has accumulated that it plays an essential role in several brain functions such as nociception, anxiety, memory, sleep and dopamine modulation. In mammalian brain, CCK is mainly found as an octapeptide (CCK-8) and tetrapeptide (CCK-4) and its effects are mediated by two types of receptors: CCK-A and CCK-B [1, 2]. CCK-8 acts at both receptors whereas CCK-4 shows its main activity at the CCK-B receptors. The distribution of the type-A and type-B receptors shows species differences and this fact has important clinical implications [3]. For example, CCKB binding sites are predominant in the spinal cord of rodents whereas CCK-A receptors prevail in the spinal cord of primates and humans. Therefore, the original nomenclature of peripheral alimentary (type A) and brain (type B) receptors no longer holds. It should be pointed out that, whereas the gene cckA encodes for the CCK-A receptor, the gene cckB encodes for both the CCK-B and gastrin receptor, thus indicating that the type-B binding site is better defined as CCK-B-gastrin receptor.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Woodruff GN, Hughes J (1991) Cholecystokinin antagonists. Ann Rev Pharmacol Toxicol 31: 469–501
Crawley JN, Corwin RL (1994) Biological actions of cholecystokinin. Peptides 15: 731–755
Benedetti F (1997) Cholecystokmm type A and type B receptors and their modulation of opioid analgesia. News Physiol Sci 12. 263–268
Stengaard-Pedersen K, Larsson LI (1981) Localization and opiate receptor binding of enkephalin, CCK and ACTH/beta-endorphin in the rat central nervous system. Peptides 1. 3–19
Gall C, Lauterborn J, Burks D, Seroogy K (1987) Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain Brain Res 403. 403–408
Gibbins IL, Furness JB, Costa M (1987) Pathway-specific patterns of coexistence of substance P, calcitonin gene-related peptide, cholecystokinin and dynorphm in neurons of the dorsal root ganglia of the guinea pig. Cell Tissue Res 248. 417–437
Faris PL, Komisaruk BR, Watkins LR, Mayer DJ (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 219: 310–312
Itoh S, Katsuura G, Maeda Y (1982) Caerulein and cholecystokinin suppress beta-endorphin-induced analgesia in the rat. Eur J Pharmacol 80. 421–425
Xu X-J, Puke MJC, Verge VMK, Wiesenfeld-Hallin Z, Hughes J, Hokfelt T (1993) Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathie pain in the rat Neurosci Lett 152. 129–132
Ghilardi JR, Allen CJ, Vigna SR, McVey DC, Mantyh PW (1992) Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and monkey: possible site of opiate-CCK analgesic interactions. J Neurosci 12: 4854–4866
Stanfa LC, Dickenson AH, Xu X-J, Wiesenfeld-Hallin Z (1994) Cholecystokinin and morphine analgesia. variations on a theme. Trends Pharmacol Sci 15: 65–66
Baber NS, Dourish CT, Hill DR (1989) The role of CCK, caerulein, and CCK antagonists m nociception. Pain 39. 307–328
Wang J, Ren M, Han J (1992) Mobilization of calcium from intracellular stores as one of the mechanisms underlying the antiopioid effects of cholecystokinin octapeptide. Peptides 13.947–951
North RA (1989) Drug receptors and the inhibition of nerve cells. Br J Pharmacol 98: 1328
Vanderah TW, Lai J, Yamamura HI, Porreca F (1994) Antisense oligonucleotide to the CCK-B receptor produces naltrindole-and (LeuS) enkephalin antiserum-sensitive enhancement of morphine antinociception. NeuroReport 5.2601–2605
Ossipov MH, Kovelowski CJ, Porreca F (1995) The increase in potency produced by carrageenan-induced inflammation is blocked by naltrindole, a selective delta opioid antagonist Neurosci Lett 184: 173–176
Watkins LR, Kmscheck IB, Kaufman EFS, Miller J, Frenk H, Mayer DJ (1985) Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opioids. Brain Res 327: 181–190
Dourish CT, Clark ML, Iversen SD (1988) Analgesia induced by restraint stress is attenuated by CCK and enhanced by the CCK antagonists MK-329, L-365260 and CR-1409. Soc Neurosci Abstr 14: 120
Xu X-J, Hao J-X, Seiger A, Hughes J, Hokfelt T, Wiesenfeld-Hallin Z (1994) Chronic pain-related behaviors in spinally injured rats: evidence for functional alterations of the endogenous cholecystokinin and opioid systems. Pain 56.271–277
Valverde O, Maldonado R, Fournie-Zaluski MC, Roques BP (1994) Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 270: 77–88
Zhou Y, Sun YH, Han JS (1993) Increased release of immunoreactive CCK-8 by electroacupuncture and enhancement of electroacupuncture analgesia by CCK-8 antagonist in rat spinal cord. Neuropeptides 24: 139–144
Benedetti F, Amanzio M, Maggi G (1995) Potentiation of placebo analgesia by proglumide Lancet 346. 1231
Benedetti F (1996) The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia Pain 64: 535–543
Xu X-J, Hokfelt T, Hughes J, Wiesenfeld-Hallin Z (1994) The CCK-B antagonists Ci988 enhances the reflex-depressive effect of morphine in axotomized rats. NeuroReport 5: 718–720
Dourish CT, O’Neill MF, Schaeffer LW, Siegl PKS, Iversen SD (1990) The cholecystokinin receptor antagonist devazepide enhances morphine-induced analgesia but not morphine-induced respiratory depression in the squirrel monkey. J Pharmacol Exp Ther255: 1158–1165
Price DD, Von der Gruen A, Miller J, Rafii A, Price C (1985) Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokmm antagonist. Anaesth Analg 64: 801–806
Lavigne GJ, Hargreaves KM, Schmidt EA, Dionne RA (1989) Proglumide potentiates morphine analgesia for acute postsurgical pain. Clin Pharmacol Ther 45: 666–673
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Verlag Italia, Milano
About this chapter
Cite this chapter
Amanzio, M., Benedetti, F. (1999). Clinical perspectives of cholecystokinin antagonists in pain management. In: Tiengo, M., Paladini, V.A., Rawal, N. (eds) Regional Anaesthesia Analgesia and Pain Management. Topics in Anaesthesia and Critical Care. Springer, Milano. https://doi.org/10.1007/978-88-470-2240-9_10
Download citation
DOI: https://doi.org/10.1007/978-88-470-2240-9_10
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0044-5
Online ISBN: 978-88-470-2240-9
eBook Packages: Springer Book Archive